Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
- Sponsor
- AstraZeneca
- Study ID
- NCT01329029
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast — DRUG500 µg, once daily
- Placebo — DRUGonce daily
Study Details
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects. Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.
Key Dates
- Start date
- May 31, 2011
- Status verified
- Sep 2016
- Primary completion
- Mar 31, 2014
- Completion
- May 31, 2014
Study Design
- Enrollment
- 1,945 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Roflumilastconcomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
- Placebo Comparator: Placeboconcomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
Primary Outcome Measure
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year [ Time Frame: 52 weeks ]
Related Studies
- Emphysema Research Registry and Biosample RepositoryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) StudyRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah
- Hyper Polarized Xenon-129 MRI vs Xenon-133 ScintigraphyPHASE1/PHASE2 · Recruiting · University of Virginia · Charlottesville, Virginia